Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 3, 2010, Pages

  Sayan, M ^a   Senturk O ^a   Akhan, S C ^a   Hulagu S ^a   Cekmen M B ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Drug resistance; HBsAg escape mutation; Hepatitis B virus; Nucleos(t)ide analogs

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEPATITIS B; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE FREQUENCY; GENE PRODUCTS, POL; GENES, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; NUCLEOSIDES; NUCLEOTIDES; TURKEY; YOUNG ADULT;

EID: 77957371309     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.11.039     Document Type: Article

References (47)

1. Nijhuis M., van Maarseveen N.M., Boucher C.A. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol 2009, (189):299-320.
2. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002, 25:97-106.
3. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005, 32:102-112.
4. Sheldon J., Rodes B., Zoulim F., Bartholomeusz A., Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006, 13:427-434.
5. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008, 61:766-768.
6. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2:147-151.
7. Avellon A., Echevarria J.M. Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. J Med Virol 2006, 78:24-36.
8. Bock C., Tillmann H., Torresi J., Klempnauer J., Locarnini S., Manns M.P., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122:264-273.
9. Bartholomeusz A., Locarnini S., Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006, 78:52-55.
10. Delaney W., Yang H., Westland C., Das K., Arnold E., Gibbs C.S., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833-11841.
11. Warner N., Locarnini S. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?. Antivir Ther 2009, 14:139-142.
12. Lai M.W., Yeh C.T. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13:875-879.
13. Gurol E., Saban C., Oral O., Cigdem A., Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006, 21:299-305.
14. Bozdayi G., Turkyilmaz A.R., Idilman R., Karatayli E., Rota S., Yurdaydin C., Bozdayi A.M. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection. J Med Virol 2005, 76:476-481.
15. Ozaslan M., Ozaslan E., Barsgan A., Koruk M. Mutations in the S gene region of hepatitis B virus genotype D in Turkish patients. J Genetics 2007, 86:195-201.
16. Mi{dotless}sti{dotless}k R., Bali{dotless}k I. The epidemiological analysis of viral hepatitis in Turkey. Viral hepatit 2001 2001, 10-55. Viral Hepatitle Savaşi{dotless}m Derneĝi, Istanbul. K. Ki{dotless}li{dotless}çturgay, S. Badur (Eds.).
17. Bozdayi A.M., Aslan N., Bozdayi G., Türkyilmaz A.R., Sengezer T., Wend U., et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004, 149:2115-2129.
18. Ozdemir F.T., Duman D., Ertem D., Avşar E., Eren F., Ozdoĝan O., et al. Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. Turk J Gastroenterol 2005, 16:183-187.
19. Kutlu T., Soycan L.Y., Karatayli{dotless} E., Turkyi{dotless}lmaz A.R., Yurdaydi{dotless}n C., Bozdayi{dotless} M. The first identified hepatitis B virus vaccine escape mutation in Turkey. Letter to the Editor. J Clin Virol 2006, 35:201-202.
20. Sayiner A.A., Agca H., Sengonul A., Celik A., Akarsu M. A new hepatitis B virus vaccine escape mutation in a renal transplant recipient. J Clin Virol 2007, 38:157-160.
21. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-42.
22. Knodell R.G., Ishak K.G., Black W.J., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981, 4:431.
23. Karatayli E., Karayalçin S., Karaaslan H., Kayhan H., Türkyilmaz A.R., Sahin F., et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-768.
24. Rozanov M., Plikat U., Chappey C., Kochergin A., Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res 2004, 32(Web Server issue):W654-W659.
25. Shaw T., Bartholomeusz A., Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006, 44:593-606.
26. Coleman P.F., Chen Y.C.J., Mushahwar I.K. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999, 59:19-24.
27. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997, 4:11-20.
28. Mendy M., D'Mello F., Kanellos T., Oliver S., Whittle H., Howard C.R. Envelope protein variability among HBV-infected asymptomatic carriers and immunized children with breakthrough infections. J Med Virol 2008, 80:1537-1546.
29. Sayan M., Akhan SÇ, Meric M. Naturally occurring amino acid substitutions to nucleos(t)ide analogs in treatment-naïve Turkish patients with chronic hepatitis B. J Viral Hepat 2010, 17(1):23-27.
30. Harrison T.J., Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 2006, 26:87-96.
31. Besisik F., Karaca C., Akyuz F., Horosanli S., Onel D., Badur S., et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003, 38:506-510.
32. Locarnini S., Mason W.S., Review Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422-431.
33. Torresi J., Silveira E.L., Civitico G., Walters T.E., Lewin S.R., Fyfe J., et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002, 299:88-99.
34. Villet S., Pichoud C., Villeneuve J., Trépo C., Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006, 131:1253-1261.
35. Hsu C., Yeh C., Chang M., Liaw Y.F. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007, 132:543-550.
36. Sheldon J., Ramos B., Garcia-Samaniego J., Rios P., Bartholomeusz A., Romero M., et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007, 46:279-282.
37. Papatheodoridis G.V., Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol 2008, 3:525-538.
38. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727-734.
39. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
40. Coleman P.F. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 2006, 12:198-203.
41. Oon C.J., Chen W.N. Current aspects of hepatitis B surface antigen mutants in Singapore. J Viral Hepat 1998, 5:17-23.
42. Thakur V., Kazim S.N., Guptan R.C., Hasnain S.E., Bartholomeusz A., Malhotra V., Sarin S.K. Transmission of G145R mutant of HBV to an unrelated contact. J Med Virol 2005, 76:40-46.
43. Cooreman M.P., van Roosmalen M.H., Morsche R.T., Sunnen C.M., de Ven E.M., Jansen J.B., et al. Characterization of reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring 'a' loop escape mutations. Hepatology 1999, 30:1287-1292.
44. Hou J., Wang Z., Cheng J., Lin J., Lau G.K., Sun J., et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in non-immunised surface antigen-negative Chinese carriers. Hepatology 2001, 34:1027-1034.
45. Olyaee S.A., Herbers U., Mohebbi S.R., Sabahi F., Zali M.R., Luedde T., et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol 2009, 51:647-654.
46. Osiowy C., Villeneuve J.P., Hetahcote E.J., Giles E., Borlang J. Detection of rtN236T and rtA181 V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LIPA HBV DR line probe assay (version 2). J Clin Microbiol 2006, 44:1994-1997.
47. Sayan M., Hulagu S., Akhan S.C., Şenturk O., Meric M., Cekmen M. Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients. Mikrobiyol Bul 2009, 43:425-432.